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Abstract
Early diagnosis of brain tumours is challenging and a major unmet need. Patients with brain tumours 
most often present with non-specific symptoms more commonly associated with less serious diagnoses, 
making it difficult to determine which patients to priortitise for brain imaging. Delays in diagnosis affect 
timely access to treatment, with potential impacts on quality of life and survival. A test to help identify 
which patients with non-specific symptoms are most likely to have a brain tumour at an earlier stage 
would dramatically impact on patients by prioritising demand on diagnostic imaging facilities. This 
clinical feasibility study of brain tumour early diagnosis was aimed at determining the accuracy of our 
novel spectroscopic liquid biopsy test for the triage of patients with non-specific symptoms that might 
be indicative of a brain tumour, for brain imaging. Patients with a suspected brain tumour based on 
assesement of their symptoms in primary care can be referred for open access CT scanning. Blood 
samples were prospectively obtained from 385 of such patients, or patients with a new brain tumour 
diagnosis. Samples were analysed using our spectroscopic liquid biopsy test to predict presence of 
disease, blinded to the brain imaging findings. The results were compared to the patient’s index brain 
imaging delivered as per standard care. Our test predicted the presence of glioblastoma, the most 
common and aggressive brain tumour, with 91% sensitivity, and all brain tumours with 81% sensitivity, 
and 80% specificity. Negative predictive value was 95% and positive predictive value 45%. The 
reported levels of diagnostic accuracy presented here have the potential to improve current symptom-
based referral guidelines, and streamline assessment and diagnosis of symptomatic patients with a 
suspected brain tumour. 
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Brain, Cancer, Diagnosis, Liquid Biopsy, Spectroscopy
Abbreviations: 
AED – anti-epilepsy drugs; ATR – attenuated total reflection; AUC – Area under the curve; 
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trials unit; EMERGE – Emergency Medicine Research Group; FTIR – Fourier transform 
infrared ; GP – general practioner; IR – infrared; NHS – National Health Service; NPV – 
negative predictive value; NSAIDs – non-steroidal anti-inflammatory drugs; PPV – positive 
predictive value; PSA – prostate specific antigen; ROC – receiver operating characteristics; 
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Introduction
Identifying which patients with symptoms of a possible brain tumour should have urgent brain imaging 
is challenging. In the UK, only 1 % of adult brain tumours are diagnosed through the emergency “Two 
Week Wait” referral pathway, where general practitioners (GPs) refer patients for urgent secondary 
care assessment because of a suspected tumour.1,2 For 19 % of patients with a brain tumour, diagnostic 
imaging was accessed following routine primary care referrals, and almost two thirds of patients are 
only diagnosed when they present to the emergency department.3,4 Many of these emergency patients 
will have previously seen a GP and 38% of patients with a brain tumour saw a GP five times before 
diagnosis. This suggests that there are potential missed opportunities for earlier diagnosis.5
Symptom-based referral guidelines perform poorly at identifying which patients in primary care should 
be referred for brain imaging for suspected tumour.6 Whilst presentation with more severe neurological 
symptoms usually results in rapid access to diagnostic imaging, most people with a brain tumour present 
with non-specific symptoms, such as headache, which are more likely associated with a non-tumour 
diagnosis and are diagnostically challenging. Brain tumours are rare, so a non-tumour diagnosis is much 
more likely in a primary care setting 7, which often leads to a diagnostic delay of several weeks for 
people with a brain tumour.8 In the symptomatic referred population, there is a reported prevalence of 
brain tumours between 1 and 3 %.9–11
A study of symptom-based referral pathways for suspected brain tumour reported a positive predictive 
value (PPV) of 2.8% for severe red flag symptoms in terms of detecting a brain tumour on subsequent 
brain imaging.9 Headache alone as an indicator of brain tumour has a reported PPV as low as 0.1%, and 
only increases (7.2%) when considered with more severe cognitive symptoms over longer periods of 
time.6 There is a clear need for new tests to support brain tumour diagnosis and to reduce diagnostic 
delay.
We previously reported a rapid, low-cost, spectroscopic liquid biopsy approach that has the potential to 
improve identification of which patients in a population with non-specific symptoms are likely to have 
a brain tumour.12 The spectroscopy test analyses patient blood serum and is based upon the interaction 
of infrared (IR) light with all molecules present within the patient blood serum, generating a “biological 
signal” of the sample.13,14 This signal is then classified using a diagnostic algorithm to predict cancer or 
non-cancer. Rather than being limited by analysis of single biomarkers, this signal is representative of 
the full biochemical profile of the serum droplet. This machine learning algorithm has been trained on 
a database of known disease and control patients to learn the signals of disease.15,16 Integrating this 
simple, rapid, low-cost blood test into the existing diagnostic pathway would lower the threshold for 
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expediting assessment for patients most likely to have a brain tumour and helping to ‘rule out’ a brain 
tumour diagnosis in others, reducing anxiety and the need for urgent  imaging. Early health economic 
assessment of the technology demonstrated that this blood test would fall within the cost-effectiveness 
threshold.17
We conducted the Brain – Early Detection (BRAIN-ED) single-centre cohort study to assess the 
diagnostic accuracy of our spectroscopic liquid biopsy on symptomatic patients referred for brain 
imaging from primary care with suspected brain tumour, and on patients with a new brain tumour 
diagnosis. We have previously reported values of sensitivity and specificity for this test based upon 
retrospective studies using biobank sample of cancer versus healthy controls.15,18 In this BRAIN-ED 
cohort we expect to see an attenuation of overall diagnostic performance as the test is applied to a 
















Ethical approval for the BRAIN-ED study was granted by Lothian Research and Ethics Committee 
(15/ES/0094). Two related cohorts of patients were eligible for inclusion, encompassing different 
access points on the cancer diagnostic pathway: 
- Cohort 1 – Symptomatic, referred population
Patients aged 16 or over referred within the pre-existing direct access computed tomography 
(DACT) pathway available to primary care doctors in NHS Lothian (UK) to exclude significant 
intracranial pathology. Urgent (same-day) brain imaging referrals are not included in this 
pathway. All DACT brain imaging is performed in a single neuroradiological department at the 
Department of Clinical Neurosciences, Western General Hospital, Edinburgh, Scotland. 
- Cohort 2 – New brain tumour diagnosis population
Patients aged 16 years or older with a recent diagnosis of a primary or recurrent brain tumour 
referred to the Department of Clinical Neurosciences for management were also eligible. 
For both cohorts, patients were recruited in secondary care facilities; (i) prior to brain scan for Cohort 
1, (ii) prior to surgical intervention for Cohort 2. All patients gave written informed consent. Blood 
samples were obtained during routine venepuncture using Sarstedt (Germany) Monovette 7.5 ml Serum 
Gel Z collection tubes, and were anonymised for processing and analysis. Each sample was inverted 
eight times, and allowed to clot for a minimum of one hour. Samples were centrifuged at 2200g for 15 
minutes (or equivalent) and stored at -80 ºC until analysis. Patient and sample details, including 
symptoms and concomitant drug treatments (based on a short list of common medications), were 
entered into an online clinical database designed by the Edinburgh Clinical Trials Unit (ECTU) to meet 
sufficient standards of data integrity and safety. 
Study Design
We assessed the acceptable clinical performance of the liquid biopsy test based upon previously 
reported levels of sensitivity (93.75 %) from a retrospective study of biobank samples;18 there are no 
existing biomarker tests for brain tumours in clinical use against which we could compare the 
performance of our test. Based on the reported sensitivities and specificities, and approximate 
prevalence level in the referred population, we determined that our study cohort should total 
approximately 600 patients to achieve a conservative sensitivity of 90 %, estimated to a clinically 
acceptable precision of ± 17% (half-width confidence interval). Prevalence in the population has been 
reported between 1-3 %, and the upper reported limit was used as a comparator in this study.19 As part 











s/fcab056/6204634 by guest on 06 M
ay 2021
behind the sample size calculations. If the precision of a smaller cohort was such that it provided 
sufficient symptomatic data for the next phase of algorithm development, recruitment could be ceased. 
For the interim analysis, we planned to assess the cohort precision at approximately 400 patients. The 
authors conducted a preliminary interrogation of the data after recruitment and analysis of 104 patients, 
whilst remaining blind to the clinical information; details of this analysis were included in the article 
by Butler et al.12
Spectroscopic Liquid Biopsy
Patient serum samples were analysed using our spectroscopic liquid biopsy test; a platform technology 
based upon attenuated total reflectance (ATR) – Fourier transform IR (FTIR) spectroscopy (Figure 1). 
This platform adapts traditional ATR-FTIR spectroscopy instrumentation, into a high-throughput 
alternative that is suited to clinical applications and workflows. The optical sample slides replace 
conventional internal reflection elements which are a key component of the ATR-FTIR spectroscopic 
method, and provide a low-cost alternative that allows batch processing and disposable sampling.  The 
slides used in this study contain four wells; three sample wells and one background well (Figure 1.A). 
The slide is then interfaced with commercially available FTIR spectrometers using the slide indexing 
unit, that translates each of the sample wells across the IR beam, allowing spectral collection (Figure 
1.B). A total of three spectra, per three sample wells, resulting in nine spectra per patient, are then fed 
into the diagnostic algorithm which generates the disease prediction (Figure 1.C). For further details we 
direct the reader the publication by Butler and colleagues.12
In this study, patient serum samples collected prior to brain imaging (cohort 1) or brain tumour surgery 
(cohort 2) were stored onsite at the Western General Hospital, Edinburgh, NHS Lothian, until date of 
analysis. The time-to-analysis ranged between 1 – 14 days in -80 ºC freezer storage, which previous 
investigations have demonstrated  to have no impact on sample integrity, or test accuracy.20 Samples 
were allowed to thaw for up to 30 minutes at room temperature (20-22 ºC), and inverted three times to 
ensure sufficient mixture and thawing. 
Each patient sample was prepared for spectroscopic liquid biopsy by pipetting 3 μL of serum onto three 
wells of the optical sample slides (Figure 1.A). Slides were then dried for 1 hour, in an incubator cabinet 
at 35 ºC, permitting controlled drying. We have previously shown that controlled temperature drying 
allows for stable and reproducible spectral data, due to the controlled formation of drying patterns.21 
When dried, each patient slide was then analysed using the ATR-FTIR spectroscopy platform, by 
placing the slide into the slide carriage on the slide indexing unit (Figure 1.B). In this study, a Perkin 
Elmer Spectrum 2 FTIR spectrometer (Perkin Elmer, US) was used to generate spectral data using 
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Algorithm Training
Following spectral acquisition, the nine spectra of each patient were analysed using our diagnostic 
algorithm – a machine learning model trained and tuned to accurately detect the signal of brain cancer 
(Figure 1.C). Machine learning approaches are essential for extracting diagnostic information from the 
spectral data; by eye, the average spectra of cancer and non-cancer patients are almost identical.12 We 
previously reported that this model was trained on a retrospective database of 724 known brain cancer 
and control patients, details of which can be found in the supplementary information (Supplementary 
Table 1 and 2).12 During its training phase this model learns the spectral indicators that are linked to 
brain cancer, so we can then test newly aquired spectra against the model, blinded to the disease 
phenotype. The diagnostic algorithm was developed over a planned iteration period to address key 
aspects of the model, including; spectral pre-processing, classifier choice, and classifier parameters. 
The final algorithm reported here is trained on 724 retrospective patients over multiple iterations and 
cross validation steps, and subsequently tested on the full 385 cohort described as part of this study. All 
results are reported on a per patient basis. 
Disease Prediction
A prediction is generated for each of the nine spectra acquired from each patient, and a consensus 
prediction determined which gives the overall result.  The consensus was taken as a maximum vote 
such that a final prediction of ‘cancer’ was made if five or more spectra agreed in their prediction of 
‘cancer’. Receiver operating characteristic (ROC) curves were generated by altering the probability 
threshold of the algorithm between cancer and non-cancer and noting the relative sensitivity and 
specificity.
In this study, disease predictions were generated for the anonymised cohort of patients, and were 
submitted for review as part of the interim analysis. Throughout this process, true patient disease class 
was left blind to all analysts and operators, and lead clinician Dr Paul Brennan was responsible for 
unblinding and reporting test performance against CT as a reference standard. The reference standard 
in this study was CT imaging, to confirm or refute evidence of central nervous system tumours, followed 
by diagnosis by biopsy if clinically indicated. In a previous review of 3000 patient brain CT scans 
undertaken through the same open access referral pathway for suspected brain tumours as detailed in 
this study, we reported that no brain tumour diagnoses were missed on CT alone with up to 5 years 
follow up for each patient.22 Hence CT was an adequate gold standard investigation in this study.
Data Availability















A total 405 patients were assessed for inclusion in this study, with a final eligible cohort of 385 patients 
reported (Figure 2). From January 2018 – February 2019, a total of 1011 patients were screened for 
eligibility based primary care referral pathway for brain imaging. Reasons for not participating in the 
study included appointment cancellation (n=83), patient declined study involvement (n=119), patient 
did not attended appointment (n=71), patient attended appointments at incorrect time (n=124), patient 
judged to not have capacity (n=41), language barrier to consent (n=9), and also staff availability 
(n=159). 
Serum samples from the first 405 consecutively recruited patients were assessed. Twenty patient 
samples were excluded where samples had been taken during, rather than before, surgical intervention. 
The age and gender breakdown of the cohort are presented in the supplementary material 
(Supplementary Table 1). In the eligible cohort, 385 patients samples were analysed in the pre-
specificed interim anlaysis, of which 66 patients had a confirmed brain tumour, resulting in an overall 
prevalence of 17% in this cohort (Table 1). Of the patient samples analysed, three brain tumours were 
identified through the cohort 1 - DACT pathway, and all other brain tumours were obtained from cohort 
2 . The largest proportion of the patients with a brain tumour were diagnosed with glioblastoma , the 
most common and most malignant brain tumour. Of the metastatic tumours to the brain, the most 
common originated in the lung (n=9), with the remainder orginating from breast (n=1), ovarian (n=1), 
endometrial (n=1), rectal (n=1), testicular (n=1), and carcinosarcoma (n=1) tissues, with a single tumour 
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Test performance was determined by comparison of the disease prediction generated by the 
spectroscopic liquid biopsy test, against the reported diagnosis from CT brain imaging, (Table 2). The 
performance of our test in identification of which blood samples came from patients with any brain 
tumour was 81% sensitivity and 80% specificity (Table 3). Test performance was also assessed for 
identification of the most frequent tumour, glioblastoma. Thirty-three tumours were confirmed 
histologically as glioblatoma.  Our test reported 30 true positives and 3 false negatives, giving a 
sensitivity of 91%. 
Table 2. Confusion matrix of the spectroscopic liquid biopsy predictions versus 
confirmed diagnosis via CT scan.
Imaging 
Positive Negative Total
Positive 54 65 119
Test 
Negative 13 253 266











s/fcab056/6204634 by guest on 06 M
ay 2021
The complete diagnostic performance of the interim analysis study cohort is summarised in Table 3. 
Based on the sensitivity (81%) and prevalence (17%) associated with this cohort, the sample size of 
385 patients was determined to achieve a level of precision (measured as the half-width of the 
confidence interval) of ± 9.5%.  If this level of sensitivity and prevalence were maintained in the 
remaining 200 patients as determined in the study size calculation, the total sample size of 600 would 
achieve a level of precision of ± 7.6%. These estimates of precision exceed the estimate of ± 17% which 
formed the basis of the original sample size calculation. As there was a high level of precision from the 
385 patients in the interim anlaysis cohort, this was therefore an appropriate point to report on the study, 
and also a significant dataset to contribute towards algorithm development. 
As PPV is dependent upon prevalence of disease in the patient cohort, our enriched  population yields 
an increased prevalence compared to a primary care setting, and thus a high PPV of 45%. When 
considering PPV in a primary care setting, we know from our previous analysis of open access referrals 
that the prevalence of brain tumours in patients referred by GPs for brain imaging to exclude a brain 
tumour is 1-3% (Zienius 2019). In that primary care context, using the upper limit of 3%, the PPV 
would reduce to 7.7%.
Table 3. Diagnostic performance of the spectroscopic liquid biopsy 
  95% CI
 Reported Lower Upper
Sensitivity 81% 71% 90%
Specificity 80% 75% 84%
Prevalence 17% 14% 21%
PPV 45% 36% 54%
NPV 95% 93% 98%
Accuracy 80% 76% 84%
NPV – negative predictive value; PPV – positive predictive value
When the threshold between cancer and non-cancer is altered within the diagnostic algorithm, it is 
possible to observe the relationship between sensititvity and specificity of the test, and determine overall 
performance (Figure 3). The area under the ROC curve suggests good binary classification between 
cancer and non-cancer, with a similar relationship between sensitivity and specificity shown. There is 
a slight skew towards high specificity, which is likely due to the bias in the patient cohort towards non-
cancer. Interestingly, in this study we report accuracy based upon the most balanced model between 
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small amount could yield a most sensitive model. For example, at a specificity of 78%, it is possible to 
achieve a sensitivity of 84%.
Metadata Investigations
Table 4 describes the patient metadata breakdown of the 385 patients in the interim-analysis cohort. We 
observed the expected change in brain tumour incidence with age, and this was mirrored in variation 
by age of referrals with suspected cancer who transpired to not have tumours (Supplementary Table 
3).
Table 4. Overview of available metadata from interim analysis patient cohort. 






< 1 month 10 49
< 6 months 14 31




















15 + 26 47







Yes 20 17Anti-epileptic drugs
No 49 299

























S. Obese 0 2
BMI
NA 3 22
BMI – body mass index; NSAID – non-steroidal anti-inflammatory drugs
Patient metadata was also used to explore the diagnoses predicted by the spectroscopic liquid biopsy 
test in order to understand whether there were any clinical factors which explained test performanc; 
however, no clear patterns could be ascertained. The patient distribution of age for incorrect diagnoses 
mirrored correct diagnoses (Supplementary Figure 1). Drug administration in the patient cohort was 
as expected; a higher proportion of patients in cohort 2 were taking steroids, and anti-epilepsy drugs 
(AEDs), for control of brain oedema and seizures, respectively, when compared to cohort 1. Other drugs 
were evenly administered between cancer and non-cancer patients. These medications did not impact 
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Discussion
We have reported the first full analysis of our study of a spectroscopic liquid biopsy test for brain 
tumours. We demonstrated that the test performs with 91% sensitivity for the most common brain 
tumour, glioblastoma, and 81% sensitivity and 80% specificity for all brian tumours. There is a clear 
clinical utility for this spectroscopic liquid biopsy.
A strength of this study is that patient samples were blinded before analysis. This provides an insight 
into how this test would perform in routine clinical practice. Most patients in our study cohort were 
referred from primary care for brain imaging to exclude a significant intracranial pathology, such as a 
brain tumour. Three patients (0.9%) referred from primary care for open access CT had a new brain 
tumour diagnosis, consistent with the reported 1-3% rate of brain tumours in the referred symptomatic 
primary care patient population.9,19 The overall prevalence of tumours in our study cohort was 17%, 
which reflects inclusion of patients with brain tumours prior to surgery. This was necessary to provide 
further positive events within the study to permit greater understanding of test performance and 
accuracy. 
In this enriched patient cohort we present a PPV of 45% for the presence of a tumour on brain imaging 
in patients with a positive spectrocspy test result. If we consider the true prevalence of brain tumours 
in the target referred symptomatic population, considered as an average prevalence of 3%, the 
equivalent PPV from our data equates to 7.7 %. This has great promise in comparison to the 
performance of symptom-based referral pathways. This provides more than a 70-fold improvement in 
brain tumour detection compared to headache alone, and also an improvement on the performance of 
symptoms based referral pathways. An examination of the NICE 2005 and Kernick referral guidelines 
for symptoms suggestive of brain tumour reported a PPV of 2.9 and 2.8 for the ’symptoms related to 
CNS’ and ‘red flag symptoms’ respectively.22 The spectroscopy test is even more beneficial in the 
patients with non-specific symptom groups where PPV of symptom based referral pathways is 0.2-
0.8%. The spectroscopic liquid biopsy test will effectively support clinician decision making, allowing 
earlier referral for diagnostic imaging of symptomatic patients most likely to have a brain tumour. This 
means that positive cases can be referred earlier, but also that negative cases can also be used to rule 
out unnecessary referrals based on a 95% NPV level. 
The test performed best in patients with glioblastoma (n=33), with a sensitivity of 91%. Glioblastoma 
is the most common and most aggressive brain tumour, so this is an important finding. Earlier diagnosis 
of glioblastoma will translate into better patient outcomes, for at least a proportion of patients. If the 
tumour is detected when it is smaller, there is greater likelihood of achieving a complete surgical 
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smaller will be associated with less risk of surgical morbidity. The high performance of the test for 
glioblastoma may reflect that glioblastoma cases were the dominant brain tumour in the 724-patient 
training database, constituting 53% of tumours.12 Fewer training samples of other tumour types may 
lead to inaccurate diagnosis of those less common cancers. At the next stage of algorithm development, 
we plan to increase numbers of non-glioblastoma brain tumours to investigate whether this improves 
the performance of the test for ‘all brain tumours’. 
The test will be of most value to primary care doctors as a rule-out tool, supporting their clinical decision 
based on patient history and examination. Approximately 98% of patients presenting with symptoms in 
primary care suggestive of a brain tumour do not have a tumour.9,24,25 In this population, a test reporting 
a low brain tumour likelihood could support a decision to observe a patient for longer rather than refer 
for immediate brain imaging. If the patients symptoms then resolve, an unnecessary CT scan will have 
been avoided, and the patient will not have the anxiety of waiting for the scan. Brain imaging can also 
have a negative benefit-to-harm profile in patients with relatively minor symptoms if the imaging leads 
to further invasive testing because of a false positive result or incidental findings. This scenario can 
cause unnecessary anxiety and may cause harm from treatment for a disease which would never 
otherwise have presented within the patient’s lifetime, such as a small incidental meningioma.26
Based on the current reported levels of accuracy, a negative result is correct in 19 out of 20 patients, 
helping to minimise the number of unnecessary referrals to imaging facilities. In the 1 in 20 patients 
incorrectly reported as negative, the progression of symptoms and continued observation would ensure 
referral occurred soon afterwards by the assessing clinician. Use of the test as a triage tool in primary 
care could therefore potentially provide cost savings to the NHS and other health services.17 The direct 
access CT brain imaging symptom-based referral pathway utilised in this study undertakes 60 negative 
CT scans for every one positive scan, highlighting the number of potentially unnecessary 
investigations.9 The addition of our liquid biopsy test could reduce the number of CT scans from 60 
down to as few as 12 scans for every positive diagnosis. This would ensure patients most in need of 
brain imaging can access it more quickly. 
There are over one hundred distinct classifications of brain tumour identified by WHO, of which many 
are extremely rare, and seldom seen in a primary care setting. Our spectroscopic liquid biopsy is able 
to perform well across a range of the most common brain tumour types. The majority of brain tumour 
cases in both this patient cohort and the 724-patient retrospective dataset (used to train the diagnostic 
algorithm) are classed as glioblastoma, in line with expected prevalence in the population. At the next 
stage of algorithm development, we will add data from paients with less common brain tumours into 
the training dataset of the model to examine whether this enhances the overall diagnostic accuracy of 
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multi-centre studies will reduce any demographic bias in the training set population, and should aim to 
reflect the target population and tumour prevalence more closely. The low incidence of brain tumours 
in the general population makes recruitment to a randomised study in primary care very difficult and 
expensive. A cohort study approach may be preferable.  
Conclusions
Earlier diagnosis of brain tumour is a major unmet clinical need. Brain tumours are rare, symptoms are 
often non-specific, and diagnosis requires access to expensive imaging resources. Our study has 
demonstrated clear clinical utility of our test in a real-world patient cohort, and provides strong evidence 
that the test may enable earlier diagnosis of brain tumours in clinical practice. Symptomatic patients 
most likely to have a brain tumour can be prioritised for brain imaging, whilst unnecessary imaging 
referrals can be avoided. This will improve the efficiency of the current diagnostic pathway which will 
provide benefits to both patients and health service providers. A liquid biopsy for these patients will 
mean a reduction in time-to-diagnosis and time-to-treatment, positively impacting on quality of life. 
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Figure Legends
Figure 1. The spectroscopic liquid biopsy platform. (A) optical sample slides containing four wells, 
for triplicate sample measurements and a single background measurement; (B) slide indexing unit to 
integrate slides with a commercially available FTIR spectrometer and; (C) diagnostic algorithm 
contained within bespoke operating software that auto-generates a disease prediction.
Figure 2. Flow of participants through BRAIN-ED study according to standards for reporting 
diagnostic accuracy (STARD)
Figure 3. Receiver operating characteristic (ROC) curve for the spectroscopic liquid biopsy based 
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Figure 1. The spectroscopic liquid biopsy platform. (A) optical sample slides containing four wells, for 
triplicate sample measurements and a single background measurement; (B) slide indexing unit to integrate 
slides with a commercially available FTIR spectrometer and; (C) diagnostic algorithm contained within 
bespoke operating software that auto-generates a disease prediction. 











s/fcab056/6204634 by guest on 06 M
ay 2021
 
Figure 2. Flow of participants through BRAIN-ED study according to standards for reporting diagnostic 
accuracy (STARD) 
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Figure 3. Receiver operating characteristic (ROC) curve for the spectroscopic liquid biopsy based on the 
symptomatic patient cohort. The reported test performance is highlighted in red. (AUC; area under the 
curve). 
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Abbreviated Summary
Brennan et al. show a rapid, low-cost blood test can identify which patients with suspected 
brain tumour to prioritise for diagnostic imaging, reducing time to diagnosis. The test is more 
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